News & Updates
Filter by Specialty:
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
Tofacitinib on par with TNFi in rheumatoid arthritis
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
Tofacitinib on par with TNFi in rheumatoid arthritis
19 May 2022
Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies
In the treatment of young infants with nonbacteraemic urinary tract infection (UTI), administering intravenous (IV) antibiotics for less than 48 hours appears to work well in the absence of meningitis, with low rates of treatment failure and serious complications, according to a study.